Antidepressant treatment strategy with an early onset of action improves the clinical outcome in patients with major depressive disorder and high anxiety: a multicenter and 6-week follow-up study

作     者：Xue-Mei Liao Yun-Ai Su Ying Wang Xin Yu Tian-Mei Si Liao Xue-Mei;Su Yun-Ai;Wang Ying;Yu Xin;Si Tian-Mei

作者机构：Peking University Sixth Hospital Peking University Institute of Mental HealthBeijing 100191China National Clinical Research Center for Mental Disorders(Peking University Sixth Hospital)Key Laboratory of Mental Health(Peking University)Beijing 100191China The 984th Hospital of Chinese People's Liberation ArmyBeijing 110108China 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2020年第133卷第6期

页      面：726-728页

核心收录：

学科分类：1002[医学-临床医学] 100205[医学-精神病与精神卫生学] 10[医学] 

基　　金：This study was sponsored by Sumitomo Dainippon Pharma Co.,Ltd.(Suzhou,China.No.SPC-SED1102) The analysis and writing were partially supported by the National Key Technology R&D Program(No.2015BAI13B01) The funders had no role in the study design,collection analysis,conduct of the study or in the writing and preparation of the manuscript or the decision to publish. 

主　　题：patients clinical treatment 

摘      要：Major depressive disorder(MDD)is a prevalent,often chronic,and highly disabling multidimensional psychiatric illness.[1] Moreover,co-occurring anxiety symptoms are extremely common among patients with MDD;up to 90%of patients present with anxiety symptoms.[2]Notably,high levels of anxiety symptoms may predict worse clinical outcomes because of poor response to pharmacotherapy for MDD.[3]So use of augmentation or combination strategies during early course of treatment could be necessary,but ensuring the accurate and timely change is difficult because of the lack of consensus to assess the early improvement of initial treatment.To date,replicated evidence indicates that the lack of early improvement(eg,20% reduction in a depression scale score)in 2 weeks can be an accurate predictor to identify eventual non?responders?4*This study aimed to evaluate the early onset of antidepressant action and clinical outcomes in patients with MDD and high anxiety,and to explore the potential influencing factors of early onset improvement.